Ilexsaponin A |
Catalog No.GC38566 |
La ilexsaponina A, aislada de la raÍz de Ilex pubescens, atenÚa la lesiÓn miocÁrdica inducida por isquemia-reperfusiÓn a través de la vÍa antiapoptÓtica.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 108524-93-2
Sample solution is provided at 25 µL, 10mM.
Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes[1].
Ilexsaponin A significantly reduces proapoptotic proteins including caspase-3, cleaved caspase-3 and bax and increases anti-apoptotic protein bcl-2 in hypoxia/reoxygenation cardiomyocytes. Ilexsaponin A treatment increases the expression levels of p-Akt in hypoxia/reoxygenation cellular model and myocardial ischemia/reperfusion animal model[1].
Ilexsaponin A (10 or 40 mg/kg) reduce the myocardial infarct size in a dose dependent manner in male Sprague-Dawley rats weighing 280-320 g[1].
[1]. Zhang SW, et al. Ilexsaponin A attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. PLoS One. 2017 Feb 9;12(2):e0170984.
Average Rating: 5
(Based on Reviews and 8 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *